Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium

BACKGROUND: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of Cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. METHODS: Patients were observed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Alva, Ajjai, Slovin, Susan, Daignault, Stephanie, Carducci, Michael, DiPaola, Robert, Pienta, Ken, Agus, David, Cooney, Kathleen, Chen, Alice, Smith, David C., Hussain, Maha
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3175265/
https://ncbi.nlm.nih.gov/pubmed/21049281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9573-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars